

Kelly R. Peck, Ph.D.

## CURRICULUM VITAE

Position: Research Assistant Professor  
University of Vermont College of Medicine, Department of Psychiatry (primary)  
University of Vermont Department of Psychological Science (secondary)

Address: 1420 University Health Center  
Department of Psychiatry  
College of Medicine  
University of Vermont  
Burlington, VT 05405  
Voice: (802) 656-9610  
email: Kelly.Peck@uvm.edu  
Website: <http://www.med.uvm.edu/behaviorandhealth>

### EDUCATION

Year	Institution	Degree	Area of Degree, Accolades
2007-2010	University of Memphis Memphis, TN	B.A.	Psychology, Magna Cum Laude
2011-2014	University of Mississippi Oxford, MS	M.A.	Clinical Psychology
2011-2017	University of Mississippi Oxford, MS	Ph.D.	Clinical Psychology
2016-2017	University of Mississippi Medical Center/G.V. (Sonny) Montgomery VAMC Jackson, MS	Clinical Psychology Predoctoral Internship	Clinical Psychology
2017-2019	University of Vermont Burlington, VT	NIH Postdoctoral Fellow	Behavioral Economics & Behavioral Pharmacology

### LICENSES, CERTIFICATION

Years	License/Certification
2019-Present	Licensed Psychologist - Doctorate, State of Vermont

### FACULTY POSITIONS HELD

Years	Institution	Academic Title	Department
-------	-------------	----------------	------------

2019-Present	University of Vermont	Assistant Professor	Psychiatry (primary) Psychological Science (secondary)
--------------	-----------------------	---------------------	---

## OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD

Years	Location/Program Name	Role
2019-Present	<b>Graduate College, University of Vermont</b> The Graduate College at the University of Vermont was formally established in 1952, though the first graduate degree had been awarded in 1807. The Graduate College includes programs and degrees in the natural, physical and biological sciences, the social sciences, the humanities, and professional training. Notably, many programs are interdisciplinary, especially in the biological and biomedical sciences as well as in environmental and ecological programs.	Faculty Member
2019-Present	<b>Vermont Center on Behavior and Health (P20 GM103644)</b> The Vermont Center on Behavior and Health (VCBH) was established in 2013 and is funded by a NIGMS Centers of Biomedical Research Excellence (COBRE) Award. The VCBH's participating investigators, collaborators, and advisors extend across 15 academic departments in the College of Medicine, 7 colleges within the University of Vermont and 5 additional universities. The focus of our center is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk and developing effective interventions and policies to promote healthy behavior. I serve as a Project Leader for our COBRE center grant.	Project Leader
2021-Present	<b>UVM Center on Rural Addiction (UVM CORA)</b> UVM CORA was established in 2019 and is funded by a \$17 million RCORP-RCOE Center of Excellence Award from the Health Resources & Services Administration. The aim of our Center is to disseminate science-based treatments and tools to rural communities throughout New England and nationally, with the overarching goal of expanding opioid use disorder (OUD) treatment capacity and reduce opioid-related morbidity and mortality in the rural areas so disproportionately impacted by the current opioid epidemic. Our collaborating partners include the University of New Hampshire and the University of Southern Maine.	Director of Clinical Operations

## HONORS AND AWARDS

Year	Name of Award
2011-2016	Graduate Research Fellowship, University of Mississippi
2012 & 2013	St. Jude Children's Research Hospital Student Travel Award
2013, 2015 & 2017	University of Mississippi Graduate Student Travel Award
2015	John and Lillian Wolfe Graduate Award for Excellence, University of Mississippi

2015	Graduate Achievement Award in Psychology, University of Mississippi
2017	University of Mississippi Medical Center Student Travel Award
2019	Director's Travel Award, National Institute on Drug Abuse
2020	The College on Problem of Drug Dependence, Travel Award for Early Career Investigators

## **KEYWORDS/AREAS OF INTEREST**

Substance use disorders, opioids, buprenorphine, methadone, posttraumatic stress disorder, prolonged exposure therapy, anxiety disorders, chronic pain, adolescents, young adults

## **SUMMARY OF PROFESSIONAL ACTIVITIES- OVERALL**

I am a Research Assistant Professor in the Department of Psychiatry in UVM's Larner College of Medicine, with a secondary appointment in UVM's Department of Psychological Science. After completing my postdoctoral fellowship, I joined the Psychiatry faculty in March of 2019 when I received a research grant from the National Institutes of General Medical Sciences. As the Primary Investigator on this R21-equivalent project that is funded through a Center of Biomedical Research Excellence (COBRE) P20 award, I have developed and evaluated a novel protocol to improve prolonged exposure (PE) therapy session attendance and reduce posttraumatic stress disorder (PTSD) symptoms among opioid use disorder (OUD) patients with co-occurring PTSD. In June of 2023, I received funding for my first R01 award from The National Institute on Drug Abuse to evaluate a telemedicine-based approach for delivering PE that has the potential to extend access to evidence-based PTSD treatment to patients receiving medications for OUD (MOUD) in rural and other underserved communities.

In addition to this programmatic research aimed at developing and evaluating cognitive-behavioral treatments for PTSD, I recently coordinated two randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated OUD. As part of these efforts, I have published 26 manuscripts in peer-reviewed scientific journals and present my research at numerous national and international scientific meetings annually. I have also co-authored chapters in 2 well-regarded textbooks.

I am also dedicated to clinical and scientific service. Since joining the Vermont Center on Behavioral and Health (VCBH) as a postdoctoral fellow and COBRE Project Director, I have provided evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic. I also obtained licensure as a clinical psychologist in Vermont in 2019. Furthermore, as the Director of Clinical Operations for the UVM Center on Rural Addiction, I am leading efforts to serve providers throughout New England by providing education, technical assistance and workforce development to providers and staff in rural, underserved communities.

As part of the UVM Larner College of Medicine's preparation for the LCME Accreditation process, I was also selected by the Department Chair to serve as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement. I am also serving on the UVM Psychiatry Compensation Committee. Additionally, I have been a member of The College on Problems of Drug Dependence (CPDD) since 2017, which is the oldest and largest organization dedicated to advancing the scientific study of substance use. I have served CPDD as a Travel Awards and Membership Committee member since 2017. Furthermore, I serve as an ad hoc reviewer for 18 journals.

Finally, since joining the VCBH research faculty, my role has involved training, supervising, and mentoring medical students, pre- and postdoctoral fellows, and research project staff and therapists. I also serve as a primary research mentor for a doctoral students as

part of the UVM clinical psychology doctoral program. As a result, I published several recent papers as with VCBH pre- and post-doctoral fellows. Additionally, I have served as a member of seven thesis or dissertation committees.

Overall, I have sought to maintain high levels of productivity in clinical research, clinical and scientific service, mentoring and teaching since joining the Department of Psychiatry faculty in 2019.

## **SUMMARY OF ACCOMPLISHMENTS**

- PI on an R01 grant from the NIH
- \$952,207 in funding as PI on an R21-equivalent COBRE P20 award
- 26 peer-reviewed articles and 2 book chapters
- As the Director of Clinical Operations for the UVM Center on Rural Addictions, I provide administrative leadership, oversee hiring and staffing decisions, and provide functional supervision to > 17 UVM staff members. I also lead efforts in the Center to provide workforce training and education in evidence-based practices to rural providers to enhance their treatment of substance use
- Primary research mentor for doctoral students as part of the VCBH's NIDA T32 training program in addictions research and the UVM clinical psychology doctoral program and member of seven thesis and dissertation committees
- Selected by the Department Chair to serve as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement in preparation for the LCME Accreditation process at the UVM Larner College of Medicine
- Selected by the Department Chair to serve as a member of Psychiatry Department Compensation Committee
- Served as a member of the Travel Awards and Membership Committees for the College on Problems of Drug Dependence (CPDD) from 2017-Present
- 4-5 scholarly presentations annually (28 oral, 41 poster, 9 invited)
- Service as an ad-hoc reviewer for 18 journals
- Provide evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic
- Awarded the University of Mississippi's John and Lillian Wolfe Graduate Award for Excellence and Graduate Achievement Award in Psychology in 2015

## **PROFESSIONAL SERVICE**

---

### **DEPARTMENTAL SERVICE**

<b>Years</b>	<b>Department</b>		
2018-2019	Psychiatry/VCBH	Vermont Center on Behavior and Health Trainee Seminar	Organizer
2020-Present	Psychiatry/VCBH	Executive Committee, UVM Center of Biomedical Research Excellence (COBRE) at VCBH	Member

### **COLLEGE SERVICE**

2020-2021	Sub-Committee 8 Curricular Management, Evaluation, and	Member
-----------	--	--------

Enhancement in preparation for the  
LCME site accreditation visit.  
2022-Present Psychiatry Department's Compensation Member  
Committee

### **MEDICAL CENTER SERVICE**

Not applicable

### **UNIVERSITY SERVICE**

Not applicable

### **GOVERNMENT**

2021 Food and Drug Administration Member, Food and Drug Administration's Reagan  
Udall Foundation's Virtual Roundtable on  
Community Perspectives on Fentanyl Screening  
and Drug Checking

### **SOCIETY MEMBERSHIPS**

2017 – Present College on Problems of Drug Dependence (Member)  
2018 – Present Association of Behavioral and Cognitive Therapists (Member)  
2019 – Present American Psychological Association (Member)  
2019 – Present American Psychological Association Division 28  
Psychopharmacology and Substance Abuse (Member)  
2021 – Present International Society for Traumatic Stress Studies (Member)  
2021 – Present Vermont Psychological Association (Member)

### **SERVICE TO PROFESSIONAL ORGANIZATIONS**

2017-2020	College on Problems of Drug Dependence	Member, Travel Awards Committee
2022-Present	College on Problems of Drug Dependence	Member, Membership Committee

### **SERVICE TO PROFESSIONAL PUBLICATIONS**

Not applicable

### **PUBLIC SERVICE**

Years	Service Role	
2017-Present	Vermont Psychological Services	Ph.D. Clinician

### **OTHER**

**Ad hoc reviewer for 18 journals, including:** *American Journal of Preventive Medicine, Applied Psychophysiology and Biofeedback, BMJ Open, Drug and Alcohol Dependence, Experimental and Clinical Psychopharmacology, Frontiers in Psychiatry, Headache, International Journal of Behavioral Medicine, JAMA Psychiatry, Journal of Addiction Medicine, Journal of Dual Diagnosis, Journal of Rural Health, Journal of Substance Abuse Treatment, Nicotine and Tobacco Research, Pharmacology, Biochemistry, and Behavior, Preventive Medicine, Preventive Medicine Reports, Substance Use & Misuse*

### **SUMMARY OF SERVICE ACTIVITIES**

As the Project Director representative to the VCBH COBRE Executive Committee I engage in strategic planning efforts related to our Annual Behavior Change, Health and Health Disparities Conference, monthly lecture series, and annual trainee seminar.

As part of the UVM Larner College of Medicine's preparation for the LCME Accreditation process, I served as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement. More recently, as a member of the Psychiatry Department's Compensation Committee, I worked with the department chair to create a proposal to promote more equitable compensation for research faculty.

I am currently an active member of the Association of Behavioral and Cognitive Therapists, American Psychological Association, and International Society for Traumatic Stress Studies. I have also been a member of CPDD since 2017, which is the oldest and largest organization dedicated to advancing the scientific study of substance use. I served CPDD as Travel Awards and Membership Committees member from 2017-Present. Furthermore, I serve as an ad-hoc reviewer for 18 journals.

I am also dedicated to clinical and scientific service. Since joining the VCBH as a postdoctoral fellow, I have provided evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic. I also obtained licensure as a clinical psychologist in Vermont in 2019.

Finally, as the Director of Clinical Operations for the UVM Center on Rural Addiction, I am leading efforts to serve providers throughout New England by providing education, technical assistance and workforce development to providers and staff in rural, underserved communities. In 2021, I served as a member of the Food and Drug Administration's Reagan Udall Foundation's Virtual Roundtable on Community Perspectives on Fentanyl Screening and Drug Checking.

## **TEACHING**

### **FORMAL SCHEDULED COURSES**

Not applicable

### **CURRICULUM DEVELOPMENT**

Not applicable

### **POSTGRADUATE AND OTHER COURSES**

Year	Course Title	Course		Hours	Number of Learners	Learner Level
		R	E			
2019-Present	Trainee Seminar, VCBH, Department of Psychiatry	x		1 weekly	8-16	Graduate and Postdoctoral
2020	First-Year Psychological Science Seminar (AS096)	x		1	40	Undergraduate

2023	Doctor of Nursing Practice Seminar (GRNS7260)	x		1	25	Graduate
------	---	---	--	---	----	----------

**OTHER:**

- 2015-2016 Instructor, General Psychology, University of Mississippi
- 2021 – Present Director of Clinical Operations for HRSA-funded Center grant, “UVM Center on Rural Addiction”: *This RCORP-RCOE Center of Excellence (P50 DA036114) supports the training and professional development of rural providers and staff in evidence-based practices for preventing and treating addiction*

**PREDOCTORAL STUDENTS SUPERVISED OR MENTORED**

Dates	Name	Program School	Role	Current Position
2019-2021	Nathaniel Moxley-Kelly	Psychological Science, University of Vermont	Ph.D. Advisor	Graduate Student, University of Vermont
2021-2022	Serra Sozen	Medical Student	Mentor, Research Supervisor	Medical Student, University of Vermont Medical Center
2022	Saira Khadka	Vermont Biomedical Research Network, Undergraduate Summer Research Intern	Mentor, Research Supervisor	Undergraduate Student, Norwich University
2022-	Jillian Giannini	Psychological Science, University of Vermont	Ph.D. Advisor	Graduate Student, University of Vermont
2022	Ethan Kile	Vermont Biomedical Research Network, Undergraduate Summer Research Intern	Mentor, Research Supervisor	Undergraduate Student, Northern Vermont University

**DISSERTATION/THESIS COMMITTEE MEMBERSHIP**

Dates	Name	Program School	Role
2020	Alison Legrand	Psychological Science, University of Vermont	Ph.D. Dissertation Committee
2020-2022	Ashley Dobbs	Psychological Science, University of Vermont	Ph.D. Dissertation Committee
2021	Jacque Mitzner	Psychological Science, University of Vermont	Undergraduate Honors Thesis Committee Chair

2022	Tori Humiston	Psychological Science, University of Vermont	Preliminary Exam Committee
2023	William Middleton	Psychological Science, University of Vermont	Ph.D. Dissertation Committee
2023	Johanna Hidalgo	Psychological Science, University of Vermont	M.A. Thesis Committee
2023	Roxanne Harfmann	Psychological Science, University of Vermont	Ph.D. Dissertation Committee

Below are publications from my prior trainees (trainees noted in **bold**):

1. Peck, K.R., **Moxley-Kelly, N.**, Badger, G.J., & Sigmon, S.C. (2021). Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont. *Preventive Medicine, 152*. doi: 10.1016/j.ypmed.2021.106817
2. Peck, K.R., Sigmon, S.C., Badger, G.J., **Moxley-Kelly, N.**, & Higgins, S.T. (2023). Prolonged exposure therapy for PTSD in individuals with opioid use disorder: A randomized pilot study. *Addictive Behaviors, 143*, 107688. (PMID: 36989699)

### **CE/CME TEACHING**

1. **Peck, K.R.** (2020, January) Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder. Presented at the University of Vermont Center on Rural Addiction's Community Rounds Workshop Series, Burlington, VT.
2. **Peck, K.R.** (2021, July) Co-occurring PTSD and Substance Use. Presented at the Vermont Psychological Association's Workshop, Burlington, VT.
3. **Peck, K.R.** & Dunn, K. (2022, April) Non-pharmacologic Treatment of Substance Use Disorders. Presented at the University of Vermont Center on Rural Addiction's Scholarship Program, Burlington, VT.
4. **Peck, K.R.** (2023, April) Non-pharmacologic Treatment of Substance Use Disorders. Presented at the University of Vermont Center on Rural Addiction's Scholarship Program, Burlington, VT.

### **POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED**

Not applicable

### **INFORMAL TEACHING**

Year

2019

Provided consultation on the provision of exposure-based trauma therapy to graduate clinicians working for the Vermont Correctional Addictions Program (VCAP).

### **FACULTY MENTORED**

Not applicable

### **OTHER VISITING FACULTY SUPERVISED**

Not applicable

### **TEACHING AIDS**

Not applicable

### **TEACHING AWARDS AND NOMINATIONS**



Not applicable

## **SUMMARY OF TEACHING ACTIVITIES**

As discussed previously, since joining the VCBH research faculty, my role has involved training, supervising, and mentoring medical students, pre- and postdoctoral fellows, and research project staff and therapists. I also serve as a primary research mentor for doctoral students as part of the UVM clinical psychology doctoral program. As a result, I published several recent papers as with VCBH pre- and post-doctoral fellows. Additionally, I have served as a member of seven thesis or dissertation committees.

In my role as a Training Mentor, I meet regularly with each trainee to discuss scholarly readings and ongoing clinical research projects. I support trainee professional development through various activities including co-authoring and co-reviewing manuscripts for peer-reviewed scientific journals and textbooks, analyzing and discussing research data, preparing data presentations for professional meetings, and providing them with opportunities to serve various professional/scientific organizations. I also continue to participate in the weekly VCBH trainee seminar. I have also authored or co-authored chapters in 2 textbooks to facilitate the dissemination of evidencebased clinical practice to students and clinicians.

Finally, As Director of Clinical Operations for the UVM Center on Rural Addiction, I have presented in several workshop series with CE/CME credits offered to support attendance by providers in rural areas. As part of my secondary appointment in the Department of Psychological Sciences, I have also provided consultation on the provision of exposure-based trauma therapy to graduate clinicians working for the Vermont Correctional Addictions Program (VCAP).

## **RESEARCH AND SCHOLARLY ACTIVITIES**

---

### **RESEARCH AWARDS AND GRANTS**

#### **Summary of Grant Funding History:**

##### **Ongoing Research Support**

R01 DA057308 Peck (PI) 07/15/23-05/31/28

Agency: NIH/NIDA

##### **Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals with OUD**

We recently demonstrated the initial feasibility of a novel Prolonged Exposure (PE) protocol for improving therapy attendance and PTSD symptoms among individuals maintained on MOUD. We propose to expand upon those promising preliminary findings by conducting a more definitive evaluation of this novel PE intervention, utilizing a novel telemedicine platform to reach rural underserved patients, and following up on highly promising initial data suggesting that PE therapy may also be associated with improvements in illicit drug use. This study represents the first effort to examine the efficacy of PE delivered via telemedicine to individuals with OUD.

Role: PI

Total costs: : \$3,462,102

UD9RH33633

Sigmon (PI)

09/1/19-08/31/28

Agency: Health Resources & Services Administration

**University of Vermont Center on Rural Addiction**

The current US opioid epidemic represents one of the most devastating public health crises of our time. There is a critical need to leverage evidence-based tools to expand opioid use disorder (OUD) treatment capacity and reduce opioid-related morbidity and mortality in rural communities, which have been disproportionately impacted. With this HRSA center award we established the UVM Center on Rural Addiction to identify, translate, disseminate and implement science-based practices to address the rural OUD epidemic, as well as future substance use disorder epidemics as they emerge.

Role: Director of Clinical Operations

Total costs: : \$33,699,252

T32 DA007242

Higgins (PI)

09/30/90 – 07/31/23

### **Training in Behavioral Pharmacology of Drug Abuse**

This training program focuses on human behavioral pharmacology, which fills a unique niche in addiction research. Our fellows learn to identify basic behavioral and pharmacological processes underpinning addiction and to translate that knowledge into effective clinical interventions and policy.

Role: Faculty Mentor

Total costs: \$2,815,554

### **Completed Research Support**

P20GM103644

Higgins (PI)

08/01/19-07/31/23

Agency: NIGMS

Peck (PD)

### **Treating Posttraumatic Stress Disorder in Patients with Opioid Use Disorder**

The co-occurrence of opioid use disorder (OUD) and posttraumatic stress disorder (PTSD) is associated with more severe mental health symptoms and worse medications for OUD (MOUD) outcomes relative to either diagnosis alone. In research by our group and others, prolonged exposure (PE) therapy has been associated with reductions in PTSD symptom severity among patients receiving treatment for concomitant OUD. However, it is unclear to what extent observed improvements in PTSD symptom severity are a function of PE versus the effects of MOUD more generally. This project will seek to evaluate the effects of PE above and beyond MOUD for reducing PTSD symptomatology among patients with concurrent PTSD and OUD.

Role: PI

Total Period: \$952,207

R01 DA042790

Sigmon (PI)

09/01/17-01/31/23

Agency: NIH/NIDA

### **Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation**

We have developed a novel Interim Buprenorphine Treatment that leverages pharmacotherapy, state-of-the-art technology and rigorous methodology to bridge existing delays in treatment access. In an initial R34 randomized pilot study, we demonstrated reductions in illicit opioid use and risk behaviors among waitlisted opioid abusers receiving IBT. This project will seek to replicate those highly promising initial results while simultaneously evaluating generality of our findings to additional rural settings outside our single academic medical center.

Role: Key Personnel

Total Period: \$3,715,109

Agency: Laura and John Arnold Foundation

Sigmon (PI)

08/10/17-07/31/22

### **Interim Buprenorphine Treatment to reduce individual and societal harm during delays to opioid treatment: Extended duration**

We have developed a novel Interim Buprenorphine Treatment that leverages pharmacotherapy, state-of-the-art technology and rigorous methodology to bridge existing delays in treatment access. In an initial R34 randomized pilot study, we demonstrated reductions in illicit opioid use and risk behaviors among waitlisted opioid abusers receiving IBT. This project will seek to replicate those highly promising initial results while simultaneously evaluating generality of our findings to a longer treatment duration.

Role: Key Personnel

Total costs: \$776,474

Agency: Indivior, PLC

Sigmon (PI)

08/01/17 – 07/31/20

**Understanding use of opioid medications by patients and non-patients**

In this study we examined individual characteristics and factors associated with illicit (nonprescribed) buprenorphine use among adults residing in rural areas.

Role: Key Personnel

Total costs: \$235,221

Agency: University of Mississippi

Peck (PI)

04/31/16-05/01/17

Graduate Student Council Research Grant

**Factors Associated with Medication Overused Headache in Patients Seeking Treatment for Primary Headaches**

A large number of adults suffer from primary headache disorders such as migraine and tension-type headache (TTH). Many headache sufferers use acute headache medications for the treatment of headache pain and associated disability; however, the overuse of acute headache medications (>10 times/month) can paradoxically produce a progression in headache frequency in the form of medication-overuse headache (MOH). The goal of this study was to identify the variables associated with MOH in a treatment-seeking population of adults with headache so as to inform further treatment and prevention efforts.

Role: PI

Total costs: \$1,000

**Pending**

N/A

**Selected Unfunded Grant Submissions (include scoring if available)**

Not applicable

**SCHOLARSHIP**

**Publication Summary:**

26 peer-reviewed articles

2 book chapters

**Peer Reviewed Publications**

**Original Research**

1. McDermott, M. J., Peck, K. R., Walters, A. B., & Smitherman, T. A. (2013). Do migraineurs selectively attend to headache-related visual stimuli? *Headache*, 53, 356-364. (PMID: 23252468)
2. Peck, K. R., Tyc, V. L., Huang, Q., & Zhang, H. (2015). Reduction of secondhand smoke exposure in the cars of children with cancer. *Journal of Pediatric Oncology*

- Nursing*, 32, 401-409. (PMID: 25650378)
3. **Peck, K. R.**, Smitherman, T. A., & Baskin, S. M. (2015). Traditional and alternative treatments for depression: Implications for migraine management. *Headache*, 55,351-355. (PMID: 25644990)
  4. Klosky, J. L., Russell, K. M., Simmons, J. L., Foster, R. H., **Peck, K. R.**, Green, D. M., & Hudson, M. M. (2015). Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer. *Pediatric Blood and Cancer*, 62, 1630-1636. (PMID: 25900433)
  5. **Peck, K. R.**, & Smitherman, T. A. (2015). Mediator variables in headache research: Methodological critique and exemplar using self-efficacy as a mediator of the relationship between headache severity and disability. *Headache*, 55, 1102-1111. *PMID: 26247313*
  6. **Peck, K. R.**, Ehrentraut, J. H., & Anghelescu, D. L. (2016). Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting. *Journal of Opioid Management*, 12, 205-216. (PMID: 27435441)
  7. Klosky, J. L., Favaro, B., **Peck, K. R.**, Simmons, J. L., Russell, K. M., Green, D. M., & Hudson, M. M. (2016). Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. *Journal of Cancer Survivorship*, 10, 449-456. (PMID: 26572902)
  8. **Peck, K. R.**, Ehrentraut, J. H., Anghelescu, D. L. (2018). Family and peer-group substance abuse as a risk-factor for opioid misuse behaviors for a young adult with cancer-related pain – A case study. *Journal of Adolescent and Young Adult Oncology*, 7, 137-140. (PMID: 28910174)
  9. **Peck, K.R.**, Roland, M., & Smitherman, T.A. (2018). Factors associated with medication-overuse headache in patients seeking treatment for primary headache. *Headache*, 58, 648-660. (PMID: 29520765)
  10. **Peck, K. R.**, Schumacher, J. A., Stasiewicz, P. R. & Coffey S. F. (2018). Adults with comorbid posttraumatic stress disorder, alcohol use disorder, and opioid use disorder: The effectiveness of modified prolonged exposure. *Journal of Traumatic Stress*, 31, 373-382. (PMID: 29786898)
  11. **Peck, K. R.**, Coffey, S. C., McGuire, A. P., Voluse, A. C., & Connolly, K. M. (2018). A cognitive processing therapy-based treatment for veterans diagnosed with co-occurring posttraumatic stress disorder and substance use disorder: The relationship between trauma-related cognitions and outcomes of a 6-week treatment program. *Journal of Anxiety Disorders*, 15, 34-41. (PMID: 30248534).
  12. **Peck, K. R.**, Ehrentraut, J. H., Anghelescu, D. L. (2019). Provision of adequate pain management to a young adult oncology patient presenting with aberrant opioid-associated behavior – A case study. *Journal of Adolescent and Young Adult Oncology*, 8,221-224. (PMID: 30335554)
  13. Hollingsworth, D. W., Gauthier, J., McGuire, A. P., **Peck, K. R.**, Hahn, K., & Conolly, K. (2018). Intolerance of uncertainty mediates symptoms of PTSD and depression in African American Veterans. *Journal of Black Psychology*, 44, 667-688. doi.org/10.1177%2F0095798418809201
  14. **Peck, K. R.**, Parker, M. A., & Sigmon, S. C. (2019). Reasons for non-medical use of opioids among young adults: Role of educational status. *Preventive Medicine*, 128. (PMID: 30951735)
  15. **Peck, K. R.**, Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2020). Effects of interim buprenorphine treatment for opioid use disorder among emerging adults. *Drug and Alcohol Dependence*, 208. (PMID: 31991327)

16. Oleskowicz, T., Ochalek, T. A., **Peck, K. R.**, Badger, G. J., & Sigmon, S. C. (2021). Within-subject evaluation of interim buprenorphine treatment during waitlist delays. *Drug and Alcohol Dependence*, 220. (PMID: 33508690)
17. **Peck, K. R.**, Streck, J. M., Ochalek, T. A., & Sigmon, S. C. (2021). Impact of current pain status on low-barrier buprenorphine treatment response among patients with opioid use disorder. *Pain Medicine*, 22, 1205-1212. (PMID: 33585885)
18. Price, M., Albaugh, M., Hahn, S., Juliano, A. C., Fani, N., Brier, Z. M. F., Legrand, A. C., van Stolk-Cooke, K., Chaarani, B., Potter, A., **Peck, K.**, Allgaier, N., Banaschewski, T., Bokde, A. L. W., Quinlan, E. B., Desrivieres, S., Flor, H., Grigis, A., Gowland, P., Heinz, A., Ittermann, B., Martinot, J-L., Martinot, M-L. P., Artiges, E., Nees, F., Orfanos, D. P., Poustka, L., Hohmann, S., Fröhner, J. H., Smolka, M. N., Walter, H., Whelan, R., Schumann, G., Garavan, H., IMAGEN Consortium. (2021). Examination of the association between exposure to childhood maltreatment and brain structure in young adults: A machine learning analysis. *Neuropsychopharmacology*, 46, 1888-1894. (PMID: 33637836)
19. **Peck, K.R.**, Nighbor, T., & Price, M. (2021). Examining associations between impulsivity, opioid use disorder, and posttraumatic stress disorder: The additive relation between disorders. *Experimental and Clinical Psychopharmacology*, 30(5), 486-493. (PMID: 34291989)
20. **Peck, K.R.**, Moxley-Kelly, N., & Sigmon, S.C. (2021). Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont. *Preventive Medicine*, 152 (Pt. 2), 106817. (PMID: 34599919)
21. Cordoba-Grueso, W.S., **Peck, K.R.**, Eddens, K.S., T., & Parker, M.A. (2021). Investigating extra-medical opioid use and social networks among people with post-traumatic stress disorder. *Drug and Alcohol Dependence Reports*, 2, 1000022. (PMID: 36845888)
22. Price, M., Legrand, A. C., Brier, Z. M. F., van Stolk-Cooke, K., **Peck, K.**, Dodds, P. S., Danforth, C. M., Adams, Z. W. (2022). Doom scrolling during COVID-19: The negative association between daily social and traditional media consumption and mental health symptoms during the COVID-19 pandemic. *Psychological Trauma: Theory, Research, Practice, and Policy*, 14(8), 1338-1346. (PMID: 35157484)
23. **Peck, K.R.**, Sigmon, S.C., Badger, G.J., Moxley-Kelly, N., & Higgins, S.T. (2023). Prolonged exposure therapy for PTSD in individuals with opioid use disorder: A randomized pilot study. *Addictive Behaviors*, 143, 107688. (PMID: 36989699)
24. Klemperer, E.M., Wreschnig, L., Crocker, A., King-Mohr, J., Ramniceanu, A. Brooklyn, J., **Peck, K.R.**, Rawson, R.A., & Evans, E.A. (in press). The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, post-release continuation of care, and overdose. *Journal of Substance Use and Addiction Treatment*.
25. Andraka-Christou, B., Williams, M., Buksbaum, S., Karkkainen, J., Stein, B.D., Batchelder, S., **Peck, K.**, Heil, S.H., Rawson, R., & Sigmon, S.C. (in press). US state laws relevant to incentives for health behavior: A qualitative analysis. *Preventive Medicine*.
26. Sigmon, S.C., **Peck, K.R.**, Batchelder, S.R., Badger, G.J., Heil, S.H., & Higgins, S.T. (2023). Technology-assisted buprenorphine treatment in rural and nonrural settings: Two randomized clinical trials. *JAMA Network Open*, 6(9): e2331910. doi: 10.1001/jamanetworkopen.2023.31910.

**In Preparation**

1. Ross, E.L., Batchelder, S.R., **Peck, K.R.**, & Sigmon, S.C. (in preparation). Cost-effectiveness of technology-assisted buprenorphine for opioid use disorder: Analysis of three randomized trials

**Non-Peer Reviewed Publications****Review Articles**

Not applicable

**Books and Chapters**

1. **Peck, K. R.**, Johnson, Y. L., & Smitherman, T. A. (2016). Migraine. In C. Rosano, A. Ikram, & M. Ganguli (Eds.), *Neuroepidemiology (Handbook of Clinical Neurology 3<sup>rd</sup> series; Vol 138, pp. 2083-294)*. New York: Elsevier
2. Higgins S. T., Heil, S. H., & **Peck, K. R.** (2021). Substance Use Disorders. In D. Barlow (Ed.), *Clinical Handbook of Psychological Disorders (6<sup>th</sup> Edition)*, pp. 612-637. New York: Guilford Press.

**Other Scholarly Publications**

Not applicable

**Abstracts**

Not applicable

**Patents Issued or Pending**

Not applicable

**Other Creative Activities**

Not applicable

**Presentations****Regional**

1. **Peck, K. R.** (2013, July). Parent-reported secondhand smoke exposure in the car: Trends and predictors. Paper presented at Psychology Rounds, St. Jude Children's Research Hospital, Memphis, TN.
2. **Peck, K. R.**, Ehrentraut, J. H., & Anghelescu, D. L. (2014, July). Aberrant opioid-associated behavior among adolescents and young adult hematology and oncology patients. Paper presented at Psychology Rounds, St. Jude Children's Research Hospital, Memphis, TN.
3. **Peck, K. R.** & Davis, R. E. (2015, April). Differential effects of psychiatric comorbidities: Are female and treatment-seeking migraineurs more disabled by their pain? Paper presented at the University of Mississippi Conference on Psychological Science, University of Mississippi, University, MS.
4. Zhao, M. S., **Peck, K. R.**, Tynes, B. L., Scott, S., & Maack, D. J. (2016, April). Putting the E in Ew! Emotion dysregulation mediates the relation between disgust sensitivity and contamination fear. Presented at the University of Mississippi Conference on Psychological Science, University of Mississippi, University, MS.
5. Black, A. K., **Peck, K. R.**, Hamer, J. D., Smitherman, T. A. (2016, April). Relations among fear of pain, psychological flexibility, and headache-related disability. Presented

- at the University of Mississippi Conference on Psychological Science, University, MS.
6. **Peck, K. R.** (2016, October) Medication overuse headache. Presented at the University of Mississippi Three Minute Thesis Competition, University, MS.
  7. **Peck, K. R.** (2017, February) Factors associated with medication-overuse headache in patients seeking treatment for primary headache. Presented at the Annual University of Mississippi Graduate Student Council Research Symposium, University, MS.
  8. **Peck, K.R.** (2018, July) Interim buprenorphine treatment for opioid use disorder. Presented at the annual Vermont Center on Behavior and Health Scientific Trainee Retreat, Vergennes, VT.
  9. **Peck, K.R.** & Sigmon, S.C. (2019, August) Interim buprenorphine: leveraging medication and technology to bridge the gap in treatment access. Presented at the annual convention of the Northeast Regional IDEa Conference, Bretton Woods, NH.
  10. **Peck, K.R.** (2019, October) Posttraumatic Stress disorder in opioid dependent patients: the effects of prolonged exposure therapy. Presented at the Vermont Center on Behavior and Health's 7th Annual COBRE Retreat, Burlington, VT.
  11. **Peck, K.R.** (2020, October) Posttraumatic Stress disorder in individuals with opioid use disorder: the effects of prolonged exposure therapy. Presented at the Vermont Center on Behavior and Health's 8th Annual COBRE Retreat, Burlington, VT.
  12. **Peck, K.R.** (2020, October) Innovative Interventions for Rural Adults with Opioid Use Disorder. Presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  13. **Peck, K.R.** (2021, October) Posttraumatic Stress disorder in opioid dependent patients: the effects of prolonged exposure therapy. Presented at the Vermont Center on Behavior and Health's 9th Annual COBRE Retreat, Burlington, VT.
  14. **Peck, K.R.** (2022, October) Posttraumatic Stress disorder in individuals with opioid use disorder: the effects of prolonged exposure therapy. Presented at the Vermont Center on Behavior and Health's 10th Annual COBRE Retreat, Burlington, VT.
  15. **Peck, K.R.** (2023, August) Disseminating evidence based interventions for treating opioid use disorder into rural communities. Presented at the Northeast Regional IDEa Conference, Wilmington, DE.
  16. **Peck, K.R.** (2023, October) Prolonged Exposure Therapy for Adults with Concurrent Posttraumatic Stress Disorder and Opioid Use Disorder. Presented at the Vermont Center on Behavior and Health's 11th Annual COBRE Retreat, Burlington, VT.
  17. **Peck, K.R.** (2023, October) Disseminating evidence based interventions for treating opioid use disorder into rural communities. Presented at the Vermont Center on Behavior and Health's 11th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.

### **National**

1. **Peck, K.R.** (2017, June) Pain-related anxiety and the use of acute pain medications in relation to headache frequency among individuals seeking treatment for headache. Presented at the annual convention of the American Headache Society, Boston, MA.
2. **Peck, K.R.** (2019, August) Examining the impact of chronic non-cancer pain on buprenorphine treatment for opioid use disorder. Presented at the annual convention of the American Psychological Association, Chicago, IL.
3. **Peck, K.R.** (2020, June) Treating Posttraumatic Stress Disorder in Patients with Opioid Use Disorder: Attendance-Contingent Incentives to Promote Therapeutic Gains. Presented at the Contingency Management Working Group as part of the annual convention of the College on Problems of Drug Dependence.
4. **Peck, K., Moxley-Kelly, N., Cole, R., Badger, G., & Sigmon, S.** (2021, August).

- Prolonged exposure therapy for PTSD in individuals with concurrent opioid use disorder. Presented at the annual convention of the American Psychological Association.
5. **Peck, K.**, Cole, R., Badger, G., Mosca, L. & Sigmon, S. (2022, June). A Pilot Study of Prolonged Exposure Therapy for Individuals With Concurrent Posttraumatic Stress Disorder and Opioid Use Disorder. Presented at the annual convention of the College on Problems of Drug Dependence, Minneapolis, MN.
  6. Andraka-Christou, B., Williams, M., Buksbaum, S., Kark, J., Stein, B., Sigmon, S.C., Batchelder, S., **Peck, K.**, Heil, S., Rawson, R., & Higgins, S.T. (2022, June). Presented at the Contingency Management Working Group as part of the annual convention of the College on Problems of Drug Dependence, Minneapolis, MN.
  7. Batchelder, S. R., **Peck, K. R.**, Ochalek, T., Sigmon, S. C. (2022, June). mHealth intervention for improving HIV, Hepatitis C, and overdose knowledge among rural adults with opioid use disorder. Presented at the annual convention of the College on Problems of Drug Dependence, Minneapolis, MN.
  8. **Peck, K.**, Pericot-Valverde, I., Saraiya, T., & Barry, D. (2022, August). Innovative Approaches to Using Cognitive Behavioral Therapy for Individuals with Opioid Use Disorder. Presented at the annual convention of the American Psychological Association, Minneapolis, MN.
  9. **Peck, K.R.** (2023, March). Prolonged exposure therapy for adults with concurrent posttraumatic stress disorder and opioid use disorder. Presented at the Collaborative Perspectives on Addiction annual meeting, Albuquerque, NM.
  10. Giannini, J. & **Peck, K.** (2023, June). Attendance contingent financial incentives to increase attendance to telemedicine-delivered prolonged exposure therapy sessions in individuals with OUD and PTSD. Presented at the annual convention of the College on Problems of Drug Dependence.
  11. **Peck, K.R.** (2023, August). Prolonged exposure therapy for adults with concurrent posttraumatic stress disorder and opioid use disorder. Presented at the annual convention of the American Psychological Association, Washington, DC.

### **Poster - Regional**

1. **Peck, K. R.**, Buscemi, J., Murphy, J. G., Martens, M. P. McDevitt-Murphy, M. E., Pederson, A. A., Skidmore, J. R. (2009, November). Characteristics of college students who seek help for alcohol problems. Poster presented at the annual convention of the Tennessee Psychology Association, Nashville, TN.
2. **Peck, K. R.**, Buscemi, J., Murphy, J. G., (2010, April). Exploration of relations between type of residence and alcohol consumption in University of Memphis students. Poster presented at the annual University of Memphis Student Research Forum, Memphis, TN.
3. **Peck, K. R.** (2012, August). Center for Epidemiologic Studies Depression Scale (CES-D) and Middle-Eastern populations. Poster presented at the annual convention of the Mississippi Psychological Association, Gulfport, MS.
4. **Peck, K. R.** (2017, August) Factors Associated with Medication-Overuse Headache in Patients Seeking Treatment for Primary Headache. Poster presented at the annual Vermont Center on Behavior and Health Scientific Trainee Retreat, Vergennes, VT.
5. Ochalek, T. A., **Peck, K. R.**, Streck, J. M., Parker, M. A., Higgins, S.T., & Sigmon, S. C. (2017, October) Promoting smoking abstinence among patients with COPD: A novel extension of evidence-based treatment. Poster presented at the Vermont Center on Behavior and Health's 5th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT
6. Parker, M. A., **Peck, K. R.**, & Sigmon, S. C. (2018, October). Reasons for non-medical



- use of opioids among young adults in the United States: The role of educational status. Poster presented at the Vermont Center on Behavior and Health's 6th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
7. **Peck, K. R.**, Ochalek, T. A., Watson, C. H., Streck, J. M., & Sigmon, S. C. (2018, October). Effects of Interim Buprenorphine Treatment for opioid use disorder for patients with pain. Poster presented at the Vermont Center on Behavior and Health's 6th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  8. Oleskowitz, T., Ochalek, T. A., **Peck, K. R.**, Lontine, P., Crosswhite, S., Ragaven, S., Jha, K., Grujic, A., & Sigmon, S. C. (2020, October). Interim buprenorphine treatment (IBT): Preliminary outcomes over a longer duration. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  9. Ragaven, S. S., Jha, K., **Peck, K. R.**, & Sigmon, S. C. (2020, October). Where are the black, indigenous, and people of color (BIPOC) in the rural opioid epidemic? Examining treatment needs in Vermont. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  10. Moxley-Kelly, N., Badger, G., Cole, R., & **Peck, K.R.** (2020, October). Using attendance-based monetary incentives to increase attendance to prolonged exposure therapy sessions in individuals with concurrent OUD and PTSD. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  11. Cole, R. & **Peck, K.R.** (2021, October). Cigarette smoking in individuals with concurrent posttraumatic stress disorder and opioid use disorder. Poster presented at the Vermont Center on Behavior and Health's 9th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  12. Batchelder, S., Wiley, R., **Peck, K.R.**, & Sigmon, S.C. (2021, October). Characterizing smokers and non-smokers among opioid-dependent treatment seekers. Poster presented at the Vermont Center on Behavior and Health's 9th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  13. Cole, R., Mosca, L., Badger, G., Sigmon, S., **Peck, K.R.** (2022, October). A pilot study of prolonged exposure with financial incentives contingent on therapy attendance in individuals with concurrent posttraumatic stress disorder and opioid use disorder. Poster presented at the Vermont Center on Behavior and Health's 10th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  14. Batchelder, S.R., Sigmon, S., Heil, S., **Peck, K.**, Gaalema, D. (2022, October). A Model for Improvements in Contingency Management Implementation. Poster presented at the Vermont Center on Behavior and Health's 10th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  15. Khadka, S., Cole, R., Mosca, L., Badger, G., & **Peck, K.** (2023, April). Social support in individuals with concurrent posttraumatic stress disorder and opioid use disorder. Poster presented at the Vermont Biomedical Research Network Career Day, Burlington, VT.
  16. Giannini, J., Cole, R., Badger, G., Lontine, P., Sigmon, S., & **Peck, K.** (2023, October). Prolonged Exposure Therapy for Individuals with Co-Occurring Posttraumatic Stress Disorder and Opioid Use Disorder: A Randomized Clinical Trial. Poster presented at the Vermont Center on Behavior and Health's 11th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.

### **Poster - National**

1. Buscemi, J., Murphy, J. G., Martens, M. P., McDevitt-Murphy, M. E., Pederson, A. A.,

- Skidmore, J. R., & **Peck, K. R.** (2009, November). Help-seeking for alcohol use in college students: Correlates and preferred methods. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Addictive Behaviors SIG, New York, NY.
2. **Peck, K. R.**, Nicholson, J., & Tyc, V. L. (2013, April). Parent-reported exposure to second-hand smoke in motor vehicles for children on treatment for cancer. Poster presented at the National Conference in Pediatric Psychology, New Orleans, LA.
  3. Davis, R. E., **Peck, K. R.**, Hamer, J. D., & Smitherman, T. A. (2013, June). Relations between alcohol use and migraine among young adults. Poster presented at the annual convention of the American Headache Society, Boston, MA.
  4. **Peck, K. R.**, Moynahan, V. L., & Smitherman, T. A. (2013, November). Relationships between self-efficacy, headache diagnosis, and impairment. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
  5. **Peck, K. R.**, Nicholson, J., & Tyc, V. L. (2013, November). Mediation and moderation of secondhand smoke exposure (SHSe): The role of self-efficacy (SE) and perceived vulnerability in parents of pediatric cancer patients. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
  6. **Peck, K. R.**, Zhao, M. S., & Smitherman, T. A. (2015, June). Gender and its interaction with depressive symptoms as predictors of disability in chronic migraine. Poster presented at the annual convention of the American Headache Society, Washington, DC.
  7. Ochalek, T. A., **Peck, K. R.**, Badger, G. J., & Sigmon, S. C. (2018, May). Within-subject evaluation of interim buprenorphine treatment during waitlist delays. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Diego, CA
  8. **Peck, K. R.**, Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2018, May). Effects of interim buprenorphine treatment for opioid use disorder among emerging adults. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Diego, CA.
  9. **Peck, K. R.**, Ochalek T.A., Watson, C. H., Streck, J. M., & Sigmon, S. C. (2018, November). Effects of interim buprenorphine treatment for opioid use disorder for patients with pain. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Washington, DC.
  10. **Peck, K. R.**, Ochalek, T. A., Watson, C. H., & Sigmon, S. C. (2019, June). Examining the impact of chronic non-cancer pain on buprenorphine treatment response for individuals with opioid use disorder. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Antonio, TX.
  11. **Peck, K. R.**, Parker, M. A., & Sigmon, S. C. (2019, November). Reasons for non-medical use of prescription opioids among young adults: Role of educational status. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Atlanta, GA.
  12. **Peck, K. R.**, Nighbor, T. N., & Price, M. (2020, June). Impulsivity in individuals with a history of opioid use with and without posttraumatic stress disorder versus healthy controls. Poster presented at the annual convention of the College on Problems of Drug Dependence.
  13. Oleskiewicz, T. N., Ochalek, T. A., **Peck, K. R.**, Badger, G., Wiley, R. C., & Sigmon, S. C. (2020, June). Interim buprenorphine treatment: Preliminary outcomes with a longer duration. Poster presented at the annual convention of the College on Problems of Drug Dependence.

14. Wiley, R. C., Oleskowicz, T. N., Ochalek, T. A., **Peck, K. R.**, & Sigmon, S. C. (2020, June). cocaine use and urinary cotinine during interim buprenorphine treatment. Poster presented at the annual convention of the College on Problems of Drug Dependence.
15. **Peck, K. R.**, Pagan, D., Klemperer, K., Badger, G., & Sigmon, S. C. (2020, November). Prolonged exposure for treating PTSD among individuals receiving methadone or buprenorphine for opioid use disorder. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies.
16. **Peck, K. R.**, Moxley-Kelly, N., Cole, R., Badger, G., & Sigmon, S. C. (2021, June). Prolonged exposure for PTSD among individuals receiving methadone or buprenorphine for opioid use disorder. Poster presented at the annual convention of the College on Problems of Drug Dependence.
17. **Peck, K. R.**, Moxley-Kelly, N., Cole, R., Badger, G., & Sigmon, S. C. (2021, November). Prolonged exposure therapy for treating PTSD among individuals receiving methadone or buprenorphine for opioid use disorder: A pilot study. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies.
18. **Peck, K.R.**, Cole, R., Giannini, J., Badger, G., Mosca, L., & Sigmon, S. (2022, November). Prolonged exposure therapy for adults with concurrent posttraumatic stress disorder and opioid use disorder: preliminary results from two randomized pilot trials. Poster presented at the 8<sup>th</sup> Biennial National IDEA Symposium of Biomedical Research Excellence.
19. **Peck, K.R.**, Giannini, J., Cole, R., Badger, G., Mosca, L., & Sigmon, S. (2023, June). Prolonged exposure therapy for individuals with co-occurring posttraumatic stress disorder and opioid use disorder: a randomized clinical trial. Poster presented at the annual convention of the College on Problems of Drug Dependence.
20. Andraka-Christou, B., Williams, M., Buksbaum, S., Karkkainen, J., Stein, B.D., Batchelder, S., **Peck, K.**, Heil, S.H., Rawson, R., Jacobs, S., Higgins, S., & Sigmon, S.C. (2023, June). State laws regulating provision of incentives related to substance use. Poster presented at the annual convention of the College on Problems of Drug Dependence.
21. Batchelder, S., Ross, E., **Peck, K.**, & Sigmon, S. (2023, June). The cost effectiveness of interim buprenorphine treatment vs. waitlist control for opioid use disorder: an analysis of three randomized trials. Poster presented at the annual convention of the College on Problems of Drug Dependence.
22. Giannini, J., Cole, R., Badger, G., Mosca, L., Sigmon, S., & **Peck, K.** (2023, June). The effect of of prolonged exposure therapy on posttraumatic stress disorder symptom clusters in individuals with opioid use disorder. Poster presented at the annual convention of the College on Problems of Drug Dependence.
23. **Peck, K.R.**, Heil, S., Mahoney, C.T., Cole, R., & Giannini, J. (2024, June). Secondary Analysis of Trials of Prolonged Exposure Therapy Among Adults with Co-Occurring Posttraumatic Stress Disorder and Opioid Use Disorder by Gender. Poster submitted for presentation at the annual convention of the College on Problems of Drug Dependence.

### **Poster - International**

1. Ehrentraut, J. H., Jurbergs, N., **Peck, K. R.**, Canavera, K., & Willard, T. (2013, October). Treatment acceptability of a brief, single-session workshop for families of children with chronic pain. Poster presented at the International Forum on Pediatric Pain, Nova Scotia, Canada.
2. **Peck, K. R.**, Moxley-Kelly, N., Cole, R., Badger, G., & Sigmon, S. C. (2021, November). Prolonged exposure therapy for PTSD among individual receiving methadone or buprenorphine for opioid use disorder: Initial feasibility. Poster presented

at the annual convention of the International Society for Traumatic Stress Studies.

3. **Peck, K. R.,** Cole, R., Badger, G., Mosca, L., & Sigmon, S. C. (2022, November). Characterizing individuals with PTSD receiving buprenorphine or methadone for opioid use disorder. Poster presented at the annual convention of the International Society for Traumatic Stress Studies, Atlanta, GA.

### **INVITED PRESENTATIONS**

1. **Peck, K.R.** (2018, October) The Ongoing Opioid Epidemic: Barriers to Treatment, Novel Treatment Approaches, and Vulnerable Populations. Invited educational talk presented at the Fairfield University Department of Psychology, Fairfield, CT.
2. **Peck, K. R.,** Klemperer, E. (2020, February). Co-occurring Opioid Use and Mental Health Disorders. Presented to the Chittenden County Opioid Alliance as part of the monthly CommunityStat meeting, Burlington, VT.
3. **Peck, K. R.** (2020, December). PTSD in individuals with opioid use disorder: The effects of prolonged exposure therapy. Presented to Howard Center's Safe Recovery program, Virtual Presentation.
4. **Peck, K. R.** (2021, March). Posttraumatic Stress Disorder in Individuals with Opioid Use Disorder: The Effects of Prolonged Exposure Therapy. Presented to the University of Vermont Psychology Club, Virtual Presentation.
5. **Peck, K.R.** (2021, September) Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder. Presented at the Co-Occurring Collaborative Serving Maine's Noon Discussion Series, Virtual Presentation.
6. **Peck, K.R.** (2022, April) Prolonged Exposure Therapy for PTSD in Individuals with Opioid Use Disorder. Presented at the Project Harmony Mentoring Group Meeting, Virtual Presentation.
7. **Peck, K.R.** (2022, June) Innovative Interventions for Adults with Opioid Use Disorder. Presented at the Fletcher Group Building Rural Recovery Ecosystems Summit, Memphis, TN.
8. **Peck, K.R.** (2022, October) Prolonged Exposure Therapy for PTSD in Individuals with Opioid Use Disorder. Presented to the University of Vermont Psychology Biobehavioral Cluster, Burlington, VT.
9. **Peck, K.R.** (2022, December) Innovative interventions for adults with opioid use disorder. Presented at the Greater Southern California Node of the Clinical Trials Network Webinar Series focused on Using Telemedicine to Increase Access to MOUD in Rural Communities.

### **Invited Media Interviews**

1. December 2015. UM programs target stress for students for finals. Invited interview with The Daily Mississippian.
2. February 2020. This woman's research saves lives: Meet the director of UVM's Center on Rural Addiction. Invited interview with The Daily Cynic.
3. April 2021. Interim buprenorphine treatment for rural adults with opioid use disorder. Invited interview on Vermont Viewpoint on 91.1 WDEV FM.
4. May, 2022. UVM researchers probe links between opioid use and PTSD. Invited interview with WCAX.

### **Quality Improvement and Patient Safety Activities**

Not applicable

## **SUMMARY OF SCHOLARLY ACTIVITIES**

My primary research and clinical interests are two-fold. First, I have conducted research focused on the development and evaluation of novel treatments for opioid use disorder (OUD). Most recently, this has included randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated OUD. Second, I have worked extensively to address co-occurring PTSD in individuals with substance use disorders (SUDs), particularly around the delivery and evaluation of cognitive-behavioral treatments for PTSD.

Since beginning as a postdoctoral fellow at the University of Vermont, I have worked closely with Dr. Stacey Sigmon, to conduct two large randomized clinical trials evaluating a technology assisted buprenorphine (TAB) protocol for reducing illicit opioid use and other high-risk behaviors among individuals with untreated opioid use disorder (OUD). These trials demonstrate the efficacy of TAB for reducing illicit opioid use and associated risks among rural and other underserved populations.

I have been conducting programmatic research for the past five years addressing PTSD in individuals seeking treatment for OUD. Examples include cross-sectional studies examining mechanisms underlying these two conditions as well as epidemiological work demonstrating the elevated prevalence of PTSD in OUD patients and the association between PTSD and inferior OUD outcomes. I am also currently PI of an NIH-funded randomized clinical trial evaluating a telemedicine-based approach for delivering PE that has the potential to extend access to evidence-based PTSD treatment to patients receiving medications for OUD (MOUD) in rural and other underserved communities.

Finally, I am increasingly engaged in research and dissemination efforts focused on individuals with OUD and concurrent mental health conditions in rural geographic areas. I published a cross-sectional examination of characteristics associated with a history of PTSD among a sample of individuals seeking buprenorphine treatment for OUD in Vermont, the second-most rural state in the US. I now serve as the director of clinical operations for the UVM Center on Rural Addiction where our mission is to expand addiction-treatment capacity in rural counties in northern New England by providing consultation, resources, training, and evidence-based technical assistance to healthcare providers and other staff.